Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients

Dual Faces of IFN  in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity

(2016) M. Mandai et al.   CLINICAL CANCER RESEARCH

CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer

(2016) Raghvendra M. Srivastava et al.   CLINICAL CANCER RESEARCH

PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma

(2016) Asma Beldi-Ferchiou et al.   Oncotarget

In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells

(2015) Chao Niu et al.   BMC IMMUNOLOGY

CTLA-4+Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis

(2015) Hyun-Bae Jie et al.   CANCER RESEARCH

Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations

(2015) Kathryn Baksh et al.   SEMINARS IN ONCOLOGY

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy

(2014) Dass S. Vinay et al.   BMB Reports

Targeting CD137 enhances the efficacy of cetuximab

(2014) Holbrook E. Kohrt et al.   JOURNAL OF CLINICAL INVESTIGATION

Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients

(2014) B.K.M. Reddy et al.   ORAL ONCOLOGY

Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade

(2014) I. P. da Silva et al.   Cancer Immunology Research

Effects of Adjuvant Chemoradiotherapy on the Frequency and Function of Regulatory T Cells in Patients with Head and Neck Cancer

(2013) P. J. Schuler et al.   CLINICAL CANCER RESEARCH

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients

(2013) R. M. Srivastava et al.   CLINICAL CANCER RESEARCH

PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection

(2013) A. W. MacFarlane et al.   Cancer Immunology Research

Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells

(2013) Gencheng Han et al.   Frontiers in Immunology

TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

(2013) Kaori Sakuishi et al.   OncoImmunology

Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity

(2012) L. C. Ndhlovu et al.   BLOOD

Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

(2012) M. K. Gleason et al.   BLOOD

Nimotuzumab treatment of malignant gliomas

(2012) Udo Bode et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

(2012) Holbrook E. Kohrt et al.   JOURNAL OF CLINICAL INVESTIGATION

Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile

(2011) Greta Garrido et al.   CANCER BIOLOGY & THERAPY

Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity

(2011) Steve C. Lee et al.   IMMUNOLOGIC RESEARCH

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

(2010) H. E. Kohrt et al.   BLOOD

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

(2010) R. Abes et al.   BLOOD

Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR

(2010) Chetana Basavaraj et al.   CANCER BIOLOGY & THERAPY

The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

(2010) SaeGwang Park et al.   CANCER CELL

CD137 ligand signaling induces human monocyte to dendritic cell differentiation

(2010) Shaqireen Kwajah M. M. et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

(2010) Dirk Strumberg et al.   INVESTIGATIONAL NEW DRUGS

Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape

(2010) Robert L. Ferris et al.   JOURNAL OF CLINICAL ONCOLOGY

T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B

(2010) Ying Ju et al.   JOURNAL OF HEPATOLOGY

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

(2010) Melarkode S. Ramakrishnan et al.   mAbs

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

(2009) Andrés López-Albaitero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation

(2009) A. Talavera et al.   CANCER RESEARCH

A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling

(2009) Songwen Ju et al.   INTERNATIONAL IMMUNOLOGY

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

(2009) Frédéric Bibeau et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

(2009) Mary L. Disis et al.   JOURNAL OF CLINICAL ONCOLOGY

Maturation Pathways of Dendritic Cells Determine TAP1 and TAP2 Levels and Cross-presenting Function

(2009) Andrés López-Albaitero et al.   JOURNAL OF IMMUNOTHERAPY

Novel Immunogenic HLA-A*0201-restricted Epidermal Growth Factor Receptor-specific T-cell Epitope in Head and Neck Cancer Patients

(2009) Pedro A. Andrade Filho et al.   JOURNAL OF IMMUNOTHERAPY

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal

(2009) Brian T Fife et al.   NATURE IMMUNOLOGY

Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies

(2008) W. Lin et al.   BLOOD

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY